Clinical Trial Update: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) [Phase 3]

View source ↗

Summary

Phase 3 TEMPO-3 trial of flexible-dose adjunctive therapy for adults with Parkinson disease and motor fluctuations has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Snippet

Sponsor: AbbVie | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-03-25